[go: up one dir, main page]

SE0201713D0 - New methods and use III - Google Patents

New methods and use III

Info

Publication number
SE0201713D0
SE0201713D0 SE0201713A SE0201713A SE0201713D0 SE 0201713 D0 SE0201713 D0 SE 0201713D0 SE 0201713 A SE0201713 A SE 0201713A SE 0201713 A SE0201713 A SE 0201713A SE 0201713 D0 SE0201713 D0 SE 0201713D0
Authority
SE
Sweden
Prior art keywords
glutamate
vertebrate
bird
including mammal
new methods
Prior art date
Application number
SE0201713A
Other languages
English (en)
Swedish (sv)
Inventor
Tadeusz Studzinski
Piedra Jose Luis Valverde
Stefan G Pierzynowski
Original Assignee
Gramineer Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0201713(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0104385A external-priority patent/SE520842C2/sv
Application filed by Gramineer Internat Ab filed Critical Gramineer Internat Ab
Priority to SE0201713A priority Critical patent/SE0201713D0/xx
Publication of SE0201713D0 publication Critical patent/SE0201713D0/xx
Priority to JP2003545307A priority patent/JP4447913B2/ja
Priority to CNB028245253A priority patent/CN100531731C/zh
Priority to PCT/SE2002/002123 priority patent/WO2003043626A1/fr
Priority to KR1020047007846A priority patent/KR100961291B1/ko
Priority to BR0214364-0A priority patent/BR0214364A/pt
Priority to CA2467676A priority patent/CA2467676C/fr
Priority to US10/496,350 priority patent/US8603981B2/en
Priority to DK02791128.8T priority patent/DK1446112T3/da
Priority to ES02791128T priority patent/ES2431085T3/es
Priority to AU2002366111A priority patent/AU2002366111B2/en
Priority to MXPA04004904A priority patent/MXPA04004904A/es
Priority to EP02791128.8A priority patent/EP1446112B1/fr
Priority to PT2791128T priority patent/PT1446112E/pt
Priority to HK05101425.8A priority patent/HK1071059B/en
Priority to US14/101,234 priority patent/US9233088B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
SE0201713A 2001-11-23 2002-06-06 New methods and use III SE0201713D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III
EP02791128.8A EP1446112B1 (fr) 2001-11-23 2002-11-22 Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
HK05101425.8A HK1071059B (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
PT2791128T PT1446112E (pt) 2001-11-23 2002-11-22 Utilização de glutamato, derivados ou metabolitos de glutamato, análogos de glutamato ou misturas dos mesmos para o fabrico de uma composição para o tratamento da osteoporose
CA2467676A CA2467676C (fr) 2001-11-23 2002-11-22 Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
DK02791128.8T DK1446112T3 (da) 2001-11-23 2002-11-22 Anvendelse af glutamat, glutamatderivater eller metabolitter, glutamatanaloger eller blandinger deraf til fremstilling af en sammensætning til behandling af osteoporose
PCT/SE2002/002123 WO2003043626A1 (fr) 2001-11-23 2002-11-22 Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
KR1020047007846A KR100961291B1 (ko) 2001-11-23 2002-11-22 골다공증 치료용 조성물의 제조에 사용되는 글루타메이트,글루타메이트 유도체 또는 대사산물, 글루타메이트 유사체또는 이들의 혼합물의 용도
BR0214364-0A BR0214364A (pt) 2001-11-23 2002-11-22 Métodos para obter melhorada qualidade dos ossos de um vertebrado e para modular a qualidade dos ossos de um vertebrado, uso de glutamato, derivados de glutamato, ou metabólitos, análogos de glutamato ou misturas dos mesmos, e, método para inibir, prevenir ou aliviar a degradação da estrutura óssoa ou enfraquecimento óssea em um vertebrado
JP2003545307A JP4447913B2 (ja) 2001-11-23 2002-11-22 オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
US10/496,350 US8603981B2 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
CNB028245253A CN100531731C (zh) 2001-11-23 2002-11-22 谷氨酸盐、谷氨酸盐衍生物或代谢产物、谷氨酸盐类似物或其混合物在制备治疗骨质疏松症的组合物中的用途
ES02791128T ES2431085T3 (es) 2001-11-23 2002-11-22 Uso de glutamato, derivados o metabolitos de glutamato, análogos de glutamato o mezclas de los mismos para la fabricación de una composición para el tratamiento de osteoporosis
AU2002366111A AU2002366111B2 (en) 2001-11-23 2002-11-22 Use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis
MXPA04004904A MXPA04004904A (es) 2001-11-23 2002-11-22 Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis.
US14/101,234 US9233088B2 (en) 2001-11-23 2013-12-09 Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103932 2001-11-23
SE0104385A SE520842C2 (sv) 2001-11-23 2001-12-21 Användning av glutamat, glutamatderivat, glutamatmetaboliter eller glutamatanaloger för att framställa en sammansättning för behandling av osteoporos
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III

Publications (1)

Publication Number Publication Date
SE0201713D0 true SE0201713D0 (sv) 2002-06-06

Family

ID=27354772

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201713A SE0201713D0 (sv) 2001-11-23 2002-06-06 New methods and use III

Country Status (14)

Country Link
US (2) US8603981B2 (fr)
EP (1) EP1446112B1 (fr)
JP (1) JP4447913B2 (fr)
KR (1) KR100961291B1 (fr)
CN (1) CN100531731C (fr)
AU (1) AU2002366111B2 (fr)
BR (1) BR0214364A (fr)
CA (1) CA2467676C (fr)
DK (1) DK1446112T3 (fr)
ES (1) ES2431085T3 (fr)
MX (1) MXPA04004904A (fr)
PT (1) PT1446112E (fr)
SE (1) SE0201713D0 (fr)
WO (1) WO2003043626A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
SE0301947D0 (sv) * 2003-07-01 2003-07-01 Gramineer Internat Ab New method and uses
US20060247207A1 (en) * 2003-07-01 2006-11-02 Pierzynowski Stefan G Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition
US7335686B2 (en) * 2003-10-20 2008-02-26 Council Of Scientific And Industrial Research Method and composition for treating osteoporosis
PL1732575T3 (pl) 2004-02-26 2011-05-31 Osteologix As Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals
PL370937A1 (pl) * 2004-10-29 2006-05-02 Sgp & Sons Ab Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20110105617A1 (en) * 2005-01-11 2011-05-05 Sgp & Sons Ab Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof
PL372183A1 (pl) * 2005-01-11 2006-07-24 Sgp & Sons Ab Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
CN101309678B (zh) * 2005-11-15 2011-04-20 安特瑞斯公司 用于与软骨损伤有关的应用的药物
BR112013026706A2 (pt) * 2011-04-18 2016-12-27 Nestec Sa composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
CN103945858A (zh) * 2011-11-21 2014-07-23 埃默斯医疗股份有限公司 用于治疗糖尿病和相关病症的方法和组合物
CN102805857B (zh) * 2012-08-27 2014-07-02 北京紫萌同达科技有限公司 一种复方氨基酸(15)双肽(2)注射液的制备方法
CN105231038A (zh) * 2015-09-23 2016-01-13 华南农业大学 α-酮戊二酸在制备猪饲料添加剂方面的应用
AU2017306050A1 (en) * 2016-08-01 2019-03-21 Filament Biosolutions Inc. Methods of treating and preventing cancer treatment side effects
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN111820330A (zh) * 2020-07-17 2020-10-27 禹城保立康生物饲料有限公司 一种提高哺乳仔猪发育的母猪饲料
WO2025170198A1 (fr) * 2024-02-06 2025-08-14 주식회사 메타센테라퓨틱스 Composition d'activateur de transporteur de zinc

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668295A (en) * 1985-04-25 1987-05-26 University Of Dayton Surgical cements
US5310768A (en) * 1987-10-29 1994-05-10 Ab Erik Vinnars Method for improving the glutamine content in skeletal muscle and composition therefore
JPH01216924A (ja) 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
JPH04164028A (ja) 1990-02-19 1992-06-09 Miwon Co Ltd グルタミン酸モノナトリウムを主成分とする疲労快復剤およびその使用方法
JP2702322B2 (ja) * 1991-08-08 1998-01-21 フジックス株式会社 活性アミノ酸カルシウム、およびそれを含有する飲料、ならびにその製造方法
JP3551149B2 (ja) * 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5646187A (en) * 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
JP2964290B2 (ja) 1992-08-25 1999-10-18 雪印乳業株式会社 ミネラル吸収促進剤
US5380934A (en) 1992-10-29 1995-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing alanylgutamine
EP0605757B1 (fr) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Composition et aliments contenant des minéraux et de l'acide poly-gamma-glutamique
US5849695A (en) * 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
SE9303691D0 (sv) 1993-11-09 1993-11-09 Gramineer Ab New beverage
CN1060336C (zh) * 1995-12-05 2001-01-10 孔彦平 一种防治钙质缺损的药物及其制备方法
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.

Also Published As

Publication number Publication date
MXPA04004904A (es) 2005-04-11
WO2003043626A1 (fr) 2003-05-30
US20140194521A1 (en) 2014-07-10
PT1446112E (pt) 2013-10-21
AU2002366111B8 (en) 2003-06-10
US20040259766A1 (en) 2004-12-23
EP1446112A1 (fr) 2004-08-18
AU2002366111B2 (en) 2007-06-28
HK1071059A1 (en) 2005-07-08
JP4447913B2 (ja) 2010-04-07
CA2467676A1 (fr) 2003-05-30
DK1446112T3 (da) 2013-10-07
CA2467676C (fr) 2011-07-12
KR100961291B1 (ko) 2010-06-04
KR20050044589A (ko) 2005-05-12
EP1446112B1 (fr) 2013-07-17
US8603981B2 (en) 2013-12-10
BR0214364A (pt) 2004-10-26
ES2431085T8 (es) 2014-01-03
CN1602190A (zh) 2005-03-30
ES2431085T3 (es) 2013-11-25
AU2002366111A1 (en) 2003-06-10
CN100531731C (zh) 2009-08-26
JP2005518353A (ja) 2005-06-23
US9233088B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
SE0201713D0 (sv) New methods and use III
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
NO20025590D0 (no) Fenylglycin-derivater
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
GEP20084488B (en) Use of therapeutic agents for treating pain
BG106013A (en) New compounds and compositions as protease inhibitors
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
EP1670450A4 (fr) Compositions pharmaceutiques et procede d'utilisation de la levodopa et de la carbidopa
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
ATE495187T1 (de) Dalda-analoge und ihre verwendung
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
SE0402762D0 (sv) Indazole sulphonamide derivatives
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
GB2352972A (en) Use of dexmedetomidine for icu sedation
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
SE0301947D0 (sv) New method and uses
MXPA05013901A (es) Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma.
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen